Meet Vlad Bogin at the 43rd Annual J.P. Morgan Healthcare Conference | Cromos Pharma

Meet Vlad Bogin at the 43rd Annual J.P. Morgan Healthcare Conference 2025

We are thrilled to announce that Vlad Bogin, MD, FACP, CEO of Cromos Pharma, will be attending the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco, CA.

Dr. Bogin looks forward to participating in this esteemed event, connecting with industry leaders, exchanging insights, and exploring developments that are shaping the healthcare and clinical research sectors.

To schedule a meeting with Dr. Bogin, please contact us at inquiry@cromospharma.com.

#jpm2025 #jpmorgan #clinicaltrials #cro #cromospharma

CONTACT

INQUIRY@CROMOSPHARMA.COM

To arrange an introductory meeting and find out how our experience can benefit your next clinical project.

OUR PUBLICATIONS

Key Takeaways from ASH 2024 | Cromos Pharma
Reflections on ASH 2024: Transformative Breakthroughs in Hematology-Oncology
Insights into Hospital Systems and Regulatory Framework in Türkiye | Cromos Pharma
Exploring Türkiye’s Edge in Clinical Research: Insights into Hospital Systems and Regulatory Framework
Clinical Research Focus 33rd edition | Cromos Pharma
Clinical Research Focus. 35th Edition
Meet Cromos Pharma at ASH 2024
Countdown to ASH 2024: What to Expect in Breakthroughs in Hematology-Oncology
AI in Clinical Trials | Cromos Pharma
AI in Clinical Trials: 8 Groundbreaking Innovations That Defined the Year
Lung Cancer Care: New Treatment Insights | Cromos Pharma
Advancing Lung Cancer Care: New Treatment Insights Highlighted During Awareness Month
World Diabetes Day Focus: The Role of GLP-1 Agonists and SGLT2 Inhibitors in Diabetes Treatment | Cromos Pharma
World Diabetes Day Focus: The Role of GLP-1 Agonists and SGLT2 Inhibitors in Diabetes Treatment
Changing Defibrillator Pad Placement Increase Survival by 164% | Cromos Pharma
Changing Defibrillator Pad Placement Increases Survival by 164%
Stem Cells Therapy Offers New Hope for Type 1 Diabetes | Cromos Pharma
Groundbreaking Stem Cell Therapy Offers New Hope for Type 1 Diabetes: A Medical Breakthrough
How the EU CTR is Shaping the Future of Clinical Trials | Cromos Pharma
How the EU CTR is Shaping the Future of Clinical Trials: Insights and Key Challenges for Sponsors
Data Protection Representative: Understanding GDPR's Article 27 Requirement | Cromos Pharma
Do You Need a Data Protection Representative? Understanding GDPR’s Article 27 Requirement
GDPR Essentials: Data Protection Officer | Cromos Pharma
GDPR Essentials: What You Need to Know About Appointing a Data Protection Officer
Mastering EU Regulatory Compliance | Part 1 | Cromos Pharma
Mastering EU Regulatory Compliance: Key Roles of the LR, DPO, and DPR in Clinical Trials (Part 1)
World Mental Health Day | Cromos Pharma
World Mental Health Day: How Clinical Trials are Transforming Mental Health Treatments for the Future
Clinical Research Focus 33rd edition | Cromos Pharma
Clinical Research Focus. 33rd Edition
7 Breakthroughs to Watch This World Heart Day | Ai | Cromos Pharma
How AI is Revolutionizing Heart Health: 7 Breakthroughs to Watch This World Heart Day
Clinical Trials in Portugal | Cromos Pharma
Exploring Portugal’s Clinical Trials Landscape: Innovations, Infrastructure, and Opportunities
7 Reasons to Choose Central and Eastern Europe | Cromos Pharma
7 Reasons to Choose Central and Eastern Europe as Your Go-To Destination for Clinical Trials
Clinical Research Focus 32nd edition | Cromos Pharma
Clinical Research Focus. 32nd Edition
Ozempic’s Potential Link to Suicidal Thoughts | Cromos Pharma
New Study Raises Concerns Over Ozempic’s Potential Link to Suicidal Thoughts
New Research Alert: Alarming Trends in Men’s Cancer Incidence & Projections to 2050 | Cromos Pharma
New Research Alert: Alarming Trends in Men’s Cancer Incidence & Projections to 2050
Poland: Europe’s New Hub for Clinical Research | Cromos Phama
Poland: Europe’s New Hub for Clinical Research
Clinical Research Focus 31st edition | Cromos Pharma
Clinical Research Focus. 31st Edition
Revolutionary HIV Breakthrough: Is Lenacapavir the Ultimate Game-Changer? | Cromos Pharma
Revolutionary HIV Breakthrough: Is Lenacapavir the Ultimate Game-Changer?
Why Smaller CROs Are the Key to Big Wins | Cromos Pharma
Unleashing Biotech Success: Why Smaller CROs Are the Key to Big Wins
PMBoK, ISO 9001, and ICH GCP: Three Pillars of Quality in Clinical Research | Cromos Pharma
PMBoK, ISO 9001, and ICH GCP: Three Pillars of Quality in Clinical Research
Clinical Research Focus 30th edition | Cromos Pharma
Clinical Research Focus. 30th Edition
Transform Clinical Trial Practices with ICH GCP E6 R3 | Cromos Pharma
Major Enhancements Set to Transform Clinical Trial Practices with ICH GCP E6 R3
Digital Twins in Clinical Research: Revolutionizing Study Design | Cromos pharma
Digital Twins in Clinical Research: Revolutionizing Study Design
FDA's New Guidelines Impacting Clinical Trials and Gene Therapy | Cromos Pharma
FDA’s Comprehensive New Guidelines Impacting Clinical Trials and Gene Therapy